Ingelheim, Germany - Boehringer Ingelheim announced the launch of PED Essentials, a comprehensive e-learning hub designed to help patient organizations g...
As biologics and novel modalities become increasingly sophisticated, understanding molecular structure under controlled conditions tells only part ...
For emerging biopharma companies, speed, quality and scalability cannot be treated as separate priorities. As products progress t...
MaaT Pharma was informed of a negative trend during the Committee for Medicinal Products for Human Use (CHMP)’s Oral Explanation meeting which ...
Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), has established a formal collaboration with X-Chem, a data...
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the ri...
Approximately 600 patients expected to be enrolled at clinical sites across the United States, Europe, China and South America Global Phase 3 program, R...
HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...
Novartis announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of red...
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the Phase Ib/IIa clinical results of its anti-S...
Resonant Clinical Solutions, a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycl...
ONWARD Medical N.V., the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, announces ...
BioMed X, a leading innovation engine for pharma, announced the relocation of its global headquarters to LAB22 at Heidelberg Innovation Park (hip), toget...
- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of p...
© 2026 Biopharma Boardroom. All Rights Reserved.
